Clinical trials: no Known Cardiovascular
Arterial Hypertension, Diabetes Mellitus Type 2 IRC or NIR
Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels
The hypothesis of the presented study is: Telmisartan induces an increase of eNOS activity in RBC resulting in an enhanced intravascular NO bioavailability, an ameliorated RBC deformability and a reduction of RBC and platelet…
- Trial name
- ITEM (NCT00559286)
- Testing
- Telmisartan
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- RWTH Aachen University
Acute Coronary Syndrome
Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.
The purpose of this clinical trial is to study the ability of a radioactive drug called "Technetium Glucarate" to detect whether the cause of chest pain in patients entering the emergency department with no obvious signs of heart…
- Trial name
- NCT00614354
- Testing
- 99mTc-glucarate solution
- Where
- 4 sites in United States
- Volunteers
- 66 people
- Sponsor
- Molecular Targeting Technologies, Inc.
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the…
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
- Trial name
- RARE-PAH (NCT05584722)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Vanderbilt University Medical Center
Stroke, Ischemic, Atrial Fibrillation
Atrial CMR in Patients With CVA of Unknown Source and no Known AF
This research study will investigate a new method for identifying which patients should be offered blood thinners or therapies to reverse the underlying causes after stroke.
- Trial name
- CARM-AF (NCT04555538)
- Testing
- Cardiac MRI
- Where
- 3 sites in United Kingdom
- Volunteers
- 92 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Target Organs Damage, Hypertensive
Evaluation of Target Organs Damage in Hypertensive Patients
Evaluation of target organs damage in hypertensive patients with no known cardiovascular (CV) or renal disease, stratified according to level of blood pressure control
- Conditions
- Target Organs Damage, Hypertensive, no Known Cardiovascular, no Known Renal Disease
- Trial name
- PreVENT-A GP (NCT01055353)
- Where
- 905 sites in France
- Volunteers
- 1,857 people
- Sponsor
- AstraZeneca